1. Overview & Definition
Undifferentiated Pleomorphic Sarcoma (UPS), formerly known as Malignant Fibrous Histiocytoma (MFH), is an aggressive, high-grade soft tissue sarcoma (STS). It is classified as a “diagnosis of exclusion”—meaning it is diagnosed only when a sarcoma lacks specific features of differentiation (such as muscle, fat, nerve, or blood vessel lineage) upon thorough histopathological and immunohistochemical analysis.
UPS is a malignancy of mesenchymal origin characterized by significant cellular pleomorphism (variation in cell size/shape), high mitotic activity, and often areas of necrosis. It behaves aggressively with a high propensity for local recurrence and distant metastasis, most commonly to the lungs.
Key Facts at a Glance
| Feature | Details |
|---|---|
| WHO Classification | Soft tissue tumours > Undifferentiated sarcomas > Undifferentiated pleomorphic sarcoma |
| Former Name | Malignant Fibrous Histiocytoma (MFH) — term now obsolete |
| Grade | High-grade (FNCLCC Grade 2 or 3) |
| Most Common Sites | Thigh (proximal), Retroperitoneum, Upper arm, Buttock/Gluteal region |
| Peak Incidence | 6th–7th decade of life (50–70 years old) |
| Gender Predilection | Slight male predominance (1.2:1 to 1.5:1) |
| Metastatic Pattern | Hematogenous (Lungs >90% of mets; Bone, Liver, Lymph nodes rare) |
| 5-Year Survival (Localized) | ~60–70% (varies significantly by size, depth, location, margins) |
2. Epidemiology & Risk Factors
UPS is the most common subtype of soft tissue sarcoma in adults (accounting for ~15–20% of all STS), though its incidence has decreased slightly as diagnostic immunohistochemistry has improved, allowing reclassification of many “UPS” cases into specific lineages (e.g., Leiomyosarcoma, Dedifferentiated Liposarcoma).
Established Risk Factors
- Prior Ionizing Radiation: Radiation-associated UPS typically develops 10–20 years (latency range 5–30+ years) after therapeutic radiation for other cancers (e.g., breast cancer, lymphoma). These tumors often arise within the prior radiation field and carry a poorer prognosis.
- Genetic Syndromes: Rarely associated with Li-Fraumeni Syndrome (TP53 germline mutation), Neurofibromatosis Type 1 (NF1), and Retinoblastoma (RB1) hereditary syndrome.
- Chronic Lymphedema: Stewart-Treves syndrome (lymphangiosarcoma) is distinct, but chronic lymphedema can rarely predispose to UPS.
- Chemical Exposure: Weak associations with vinyl chloride, arsenic, and phenoxy herbicides (Agent Orange), though evidence is less robust than for angiosarcoma.
Non-Risk Factors
- Trauma (trauma draws attention to a pre-existing mass; it does not cause sarcoma).
- Benign soft tissue tumors (lipomas, fibromas) do not transform into UPS.
3. Pathogenesis & Molecular Biology
Unlike translocation-associated sarcomas (e.g., Synovial Sarcoma SS18-SSX, Ewing Sarcoma EWSR1-FLI1), UPS is genomically complex and heterogeneous. It lacks a single defining driver mutation.
| Molecular Feature | Description | Clinical Relevance |
|---|---|---|
| Karyotype | Highly complex, unbalanced, numerous chromosomal gains/losses | Reflects genomic instability; no diagnostic translocation. |
| Common CNAs | Gains: 1q, 5p, 8q, 12q, 17q, 20q <br> Losses: 9p, 10q, 13q, 17p, 22q | CDKN2A (9p21) loss & TP53 (17p13) mutation common. |
| Key Mutated Genes | TP53 (~50–70%), RB1, ATRX, NF1, PTEN, PIK3CA | TP53 loss correlates with high grade & radiation association. |
| TMB (Tumor Mutational Burden) | Generally Low to Intermediate | Predicts limited response to single-agent immunotherapy (checkpoint inhibitors). |
| MDM2/CDK4 Amplification | Absent (Distinguishes from Well-Differentiated/Dedifferentiated Liposarcoma) | Critical diagnostic discriminator via FISH/IHC. |
4. How Does It Look? (Pathology, Imaging & Gross Appearance)
This section details the visual characteristics of UPS across macroscopic (gross), microscopic (histology), and radiological (imaging) domains.
Gross Pathology (Macroscopic Appearance)
- Size: Typically large at presentation (median 5–10 cm; often >10 cm in retroperitoneum).
- Shape: Round, ovoid, or lobulated; often infiltrative into surrounding fascia/muscle rather than well-encapsulated.
- Consistency: Firm, fleshy, rubbery (white-tan cut surface).
- Heterogeneity: Hallmark feature. Cut surface shows variegated appearance due to:
- Hemorrhage: Dark red/black areas.
- Necrosis: Yellow-white, soft, granular zones (often central).
- Cystic change / Myxoid areas: Gelatinous, translucent patches.
- Pseudocapsule: A compressed layer of reactive fibrous tissue and displaced muscle fibers may be present but is frequently breached by tumor “fingers” (satellite nodules).
Pathologist’s Note:** *The gross heterogeneity (necrosis + hemorrhage + solid tumor) often correlates with the “pleomorphic” microscopic appearance and high grade.
Microscopic Pathology (Histology & IHC)
Diagnosis requires exclusion of specific differentiation. A panel of immunohistochemistry (IHC) is mandatory.
Histological Patterns (Often Mixed)
| Pattern | Description | Frequency |
|---|---|---|
| Storiform | Spindle cells arranged in a “cartwheel” or “matted” pattern. | Most common (“classic” MFH-like). |
| Pleomorphic (Giant Cell) | Marked nuclear atypia, multinucleated giant cells, bizarre nuclei. | High grade; mimics pleomorphic rhabdomyosarcoma/osteosarcoma. |
| Myxoid | Cells suspended in abundant mucinous (alcian blue+) stroma. | Can mimic Myxofibrosarcoma (MFS); MFS has curvilinear vessels. |
| Inflammatory | Prominent lymphoplasmacytic infiltrate; can mimic lymphoma. | Rare; requires CD45/LCA to exclude hematolymphoid malignancy. |
Diagnostic Immunohistochemistry Panel (The “Rule Out” Panel)
| Marker | Expected Result in UPS | Purpose (What it Excludes) |
|---|---|---|
| MDM2 / CDK4 | Negative (Nuclear) | Well-Differentiated / Dedifferentiated Liposarcoma (Amplified). |
| S100 / SOX10 | Negative | Melanoma, MPNST, Clear Cell Sarcoma, Myoepithelial tumors. |
| Desmin / Myogenin / MyoD1 | Negative | Rhabdomyosarcoma, Leiomyosarcoma. |
| SMA / h-Caldesmon | Negative / Focal weak | Leiomyosarcoma, Myofibroblastic tumors. |
| STAT6 | Negative | Solitary Fibrous Tumor. |
| CD34 | Negative / Focal | DFSP, Solitary Fibrous Tumor, MPNST. |
| Pan-Cytokeratin (AE1/AE3) | Negative | Carcinoma (Metastatic or Sarcomatoid), Epithelioid Sarcoma. |
| CD45 (LCA) | Negative | Lymphoma / Myeloid Sarcoma. |
| INI1 (SMARCB1) | Retained (Nuclear) | Epithelioid Sarcoma, Rhabdoid tumor (Loss = Diagnostic). |
| H3K27me3 | Retained | MPNST (Loss supports MPNST). |
| Beta-Catenin (Nuclear) | Negative | Desmoid Fibromatosis, Synovial Sarcoma (rarely). |
Diagnostic Algorithm: *If morphology suggests sarcoma + High Grade + Pleomorphism + All lineage markers negative + MDM2/CDK4 negative + INI1 retained** $rightarrow$ Diagnosis: UPS.
Radiological Appearance (Imaging)
MRI (Magnetic Resonance Imaging) is the gold standard for local staging.
| Sequence / Feature | Typical UPS Appearance | Differential Consideration |
|---|---|---|
| T1-Weighted | Low to Intermediate Signal (lower than muscle, higher than fat). | Liposarcoma = High signal (fat). Hemorrhage = High signal (subacute). |
| T2-Weighted | Heterogeneously High Signal. <br>• Solid cellular areas: Intermediate.<br>• Necrosis/Cysts/Myxoid: Very High (fluid signal). | Myxofibrosarcoma: “Tail sign” (fascial extension), more cystic. <br> Hematoma: Fluid-fluid levels, evolving signal. |
| T1 Post-Gadolinium (Fat Sat) | Heterogeneous Enhancement.<br>• Viable tumor enhances avidly.<br>• Necrotic centers do not enhance.<br>• “Septa” enhancement within cystic areas. | Abscess: Rim enhancement + edema. <br> Necrotic Lymph Node: Central necrosis + nodal shape. |
| Peritumoral Edema | Common. High T2 signal in adjacent muscle/fat (inflammatory/reactive). | Can overestimate tumor extent on MRI vs. pathology. |
| Invasion Signs | Encasement of neurovascular bundle, cortical bone erosion, fascial breach. | Critical for surgical planning (R0 resection feasibility). |
CT (Computed Tomography):
- Primary role: Chest CT for pulmonary metastasis screening (superior to MRI for lung nodules).
- Local staging: Used if MRI contraindicated; shows soft tissue mass, calcifications (rare in UPS, suggest osteosarcoma/chondrosarcoma), bone invasion.
PET-CT (FDG-PET):
- High SUVmax (typically > 4–6, often 8–15+), correlating with high grade/proliferation.
- Utility: Baseline metabolic volume, detecting occult distant mets, assessing early treatment response (neoadjuvant therapy).
5. Symptoms & Clinical Presentation
UPS is often asymptomatic in early stages. Symptoms arise from mass effect, local invasion, or metastatic spread. The clinical picture varies significantly by anatomical site.
General Presenting Features
- Painless Mass: The most common presentation (70–80%). Often present for months before consultation.
- Pain: Occurs in ~30–40% of cases. Suggests:
- Rapid growth stretching the fascia/periosteum.
- Invasion of nerves (neuropathic pain/radiculopathy).
- Invasion of bone/periosteum (deep, boring pain, worse at night).
- Rapid Growth: History of noticeable enlargement over weeks to a few months (high grade kinetics).
Site-Specific Symptomatology
| Anatomical Site | Frequency | Typical Symptoms & Signs | “Red Flag” Features Requiring Urgent Imaging |
|---|---|---|---|
| Lower Extremity<br>(Thigh > Leg) | ~45–50% | • Palpable mass (deep to fascia usually).<br>• Vague thigh/knee pain.<br>• Limping / Gait disturbance (quadriceps/hamstring involvement).<br>• Swelling (venous/lymphatic compression). | • Fixed to femur (bone invasion).<br>• Femoral nerve palsy (quadriceps wasting, knee buckling).<br>• Sciatic nerve pain (radiating down leg). |
| Retroperitoneum | ~20–25% | • Asymptomatic until very large (15–30 cm).<br>• Abdominal fullness / distension.<br>• Early satiety (gastric compression).<br>• Constipation / Obstruction (colonic compression).<br>• Flank/back pain (psoas/kidney invasion).<br>• Hydronephrosis (ureteral obstruction) $rightarrow$ renal failure. | • Ureteric obstruction (silent renal loss).<br>• IVC compression (lower limb edema).<br>• GI bleeding (mucosal invasion). |
| Upper Extremity | ~10–15% | • Shoulder/Arm mass.<br>• Restricted range of motion (shoulder/elbow).<br>• Neurovascular symptoms (Brachial plexus compression: ulnar distribution paresthesia, thenar wasting). | • Brachial plexus invasion (Horner’s syndrome if apical).<br>• Pathological fracture (humerus). |
| Head & Neck | ~5–10% | • Mass (parotid, neck, scalp, orbit, sinonasal).<br>• Cranial nerve palsies (CN VII, XII common).<br>• Nasal obstruction / Epistaxis (sinonasal).<br>• Proptosis / Diplopia (orbital). | • Airway compromise.<br>• Skull base invasion (CSF leak, cranial neuropathies). |
| Visceral / Other | Rare | • Breast (mimics carcinoma).<br>• Spermatic cord / Paratesticular.<br>• Heart / Great vessels (dyspnea, tamponade). | • Hemoptysis (pulmonary mets or primary cardiac). |
Systemic / Paraneoplastic Symptoms (Rare)
- Constitutional: Weight loss (>10% body weight), low-grade fever, night sweats, fatigue (usually signify advanced/metastatic disease).
- Hypoglycemia: Rare (IGF-II secretion – “Non-islet cell tumor hypoglycemia”).
- Coagulopathy: Disseminated Intravascular Coagulation (DIC) or venous thromboembolism (VTE) – sarcoma patients are high risk for VTE.
Physical Examination Checklist for Clinicians
When evaluating a soft tissue mass, document:
- Size: Maximum diameter in cm (measure with calipers/tape).
- Depth: Superficial (subcutaneous, above fascia) vs. Deep (beneath fascia, intramuscular, intermuscular). Depth is a major prognostic factor.
- Consistency: Soft / Firm / Hard / Fluctuant.
- Fixation: Mobile / Tethered to fascia / Fixed to bone / Neurovascular bundle.
- Skin Changes: Discoloration, ulceration, satellite nodules, venous dilation.
- Neurovascular Exam: Distal pulses, sensation, motor strength (compare bilaterally).
- Lymph Nodes: Regional basins (inguinal, axillary, cervical) – Node positivity is rare in UPS (<5%) but upstages to Stage IV.
Clinical Pearl: Any deep, painless mass > 5 cm (size of a golf ball) or any* mass growing rapidly must be investigated urgently with MRI and referred to a Sarcoma Multidisciplinary Team (MDT) before** biopsy or excision. Inappropriate “shell-out” excision contaminates planes and worsens prognosis.
6. Diagnostic Workup & Staging
The Diagnostic Pathway (Standard of Care)
- Clinical Assessment + MRI (Local): Characterize mass, relationship to neurovascular structures, fascial planes, bone.
- Core Needle Biopsy (Image-Guided): Mandatory before definitive treatment.
- Technique: 14–18G core needle; ≥ 3–4 passes.
- Guidance: Ultrasound (superficial) or CT (deep/retroperitoneal).
- Tract Planning: Biopsy tract must be placed in line with future surgical incision to allow en-bloc excision of the tract.
- Histopathology + IHC + Molecular (FISH/NGS): As detailed in Section 4.2.
- Staging Investigations (Systemic):
- Chest CT (Thin-cut, 1-3mm): Gold standard for lung mets.
- FDG-PET-CT: Optional but recommended for high-grade, large (>5cm), or retroperitoneal tumors; detects occult bone/visceral mets.
- Bone Scan / Brain MRI: Only if symptomatic (low yield for routine screening in UPS).
Staging Systems
Two systems are used concurrently:
A. AJCC 8th Edition / UICC TNM Staging (Anatomic)
| Stage | T (Size/Depth) | N (Nodes) | M (Mets) | Grade (G) |
|---|---|---|---|---|
| IA | T1 (≤5 cm) | N0 | M0 | G1 (Low) UPS is never G1 |
| IB | T2–T4 (>5 cm) | N0 | M0 | G1 UPS is never G1 |
| II | T1 (≤5 cm) | N0 | M0 | G2–G3 (High) |
| IIIA | T2 (>5 cm, Superficial) | N0 | M0 | G2–G3 |
| IIIB | T2 (>5 cm, Deep) | N0 | M0 | G2–G3 |
| IIIC | T3/T4 (Invasion/Visceral) | N0 | M0 | G2–G3 |
| IV | Any T | N1 | M1 | Any G |
Note: UPS is almost exclusively Grade 2 or 3 (High Grade). Therefore, UPS presents as Stage II, III, or IV.
B. FNCLCC Grading System (Prognostic – Used within TNM)
| Parameter | Score 1 | Score 2 | Score 3 |
|---|---|---|---|
| Differentiation | N/A (UPS = Score 3 by definition “Undifferentiated”) | 3 | |
| Mitotic Count (per 10 HPF) | 0–9 | 10–19 | ≥ 20 |
| Necrosis (% of tumor area) | < 25% | 25–50% | > 50% |
| Total Score | Grade 2 (Score 4–5) | Grade 3 (Score 6–8) |
Most UPS are Grade 3 (High mitotic count + Necrosis).
7. Treatment Strategies (Multidisciplinary Management)
Treatment must be coordinated by a Sarcoma Multidisciplinary Team (MDT) comprising Surgical Oncology, Radiation Oncology, Medical Oncology, Radiology, Pathology, and Rehabilitation.
Localized Disease (Stages II–III): Curative Intent
Surgery: The Cornerstone
- Goal: R0 Resection (microscopically negative margins).
- Technique: Wide Excision (en-bloc removal of tumor + cuff of normal tissue/fascia).
- Extremity: Limb-salvage surgery >95% feasible. Amputation reserved for major neurovascular invasion, infection, or failed salvage.
- Retroperitoneum: En-bloc visceral resection (kidney, colon, pancreas, psoas muscle) often required to achieve R0. “Organ-sparing” resection increases R1/R2 risk.
- Margins: Defined by R-status (R0, R1 microscopic+, R2 macroscopic+). Margin width (mm) matters less than fascial boundary integrity.
Radiation Therapy (RT): Essential Adjunct for High-Grade/Deep/Close Margins
| Setting | Indication | Dose / Technique |
|---|---|---|
| Preoperative (Neoadjuvant) | Preferred for Extremity/Trunk UPS. <br>• Shrinks tumor (facilitates R0).<br>• Lower dose (50 Gy) vs Post-op (66 Gy).<br>• Less long-term fibrosis/edema. | 50 Gy / 25 fractions (IMRT/VMAT).<br>Surgery ~4–6 weeks post-RT. |
| Postoperative (Adjuvant) | • Positive/Close margins (R1).<br>• Unexpected high-grade/large size found at surgery (no pre-op RT).<br>• Retroperitoneum (controversial; SELECT trial: no OS benefit for routine adjuvant RT, but local control benefit). | 60–66 Gy / 30–33 fractions (IMRT/VMAT).<br>Boost to tumor bed if close margins. |
| Intraoperative (IORT) | Boost to close margins at time of surgery (esp. retroperitoneum). | Single fraction 10–15 Gy (electrons/HDR brachy). |
Pre-op RT = Better function, higher wound complication risk (esp. lower limb). Post-op RT = Better wound healing, higher long-term stiffness/fibrosis risk.
Systemic Therapy (Chemotherapy) – Controversial in Localized UPS
- Standard: No universal standard for adjuvant chemotherapy in UPS (unlike Rhabdomyosarcoma or Ewing).
- Consideration (Individualized/Clinical Trial):
- High Risk: Grade 3, Size >10 cm, Deep, Retroperitoneal, Age < 60–70, Good performance status.
- Regimen: Doxorubicin + Ifosfamide (AI) or Doxorubicin alone.
- Evidence: Meta-analyses show ~6–10% absolute improvement in Disease-Free Survival (DFS), but no consistent Overall Survival (OS) benefit in unselected populations. Toxicity (cardiotoxicity, myelosuppression, nephrotoxicity) is significant.
- Neoadjuvant Chemo: Sometimes used for borderline resectable tumors to downstage (Response rate ~20–30% in UPS).
Metastatic / Advanced Disease (Stage IV): Palliative / Life-Prolonging Intent
Pulmonary Metastasectomy (Surgery for Lung Mets)
- Candidate Selection: Crucial.
- Controlled primary tumor.
- Complete resection (R0) of ALL lung lesions feasible.
- Long Disease-Free Interval (DFI > 12–24 months favorable).
- Few nodules (≤ 3–5), unilateral preferred.
- No extrathoracic disease.
- Outcome: 5-yr OS 25–40% after complete metastasectomy. Repeat metastasectomy possible for re-recurrence.
Systemic Therapy (First-Line)
| Regimen | Dose/Schedule | Response Rate (RR) | Median PFS | Median OS | Key Toxicity |
|---|---|---|---|---|---|
| Doxorubicin (Single Agent) | 60–75 mg/m² q21d | 15–25% | 3–4 mo | 12–18 mo | Cardiotoxicity (cum. 450–550 mg/m²), Alopecia, Nausea. |
| Doxorubicin + Ifosfamide (AI) | Doxo 60 + Ifos 6–10g/m² q21d (w/ Mesna/G-CSF) | 30–45% | 5–7 mo | 14–20 mo | High: Neutropenia, Infection, Neurotoxicity (Ifos), Cardiotoxicity. |
| Gemcitabine + Docetaxel (GemDoc) | Gem 900 d1/d8 + Doc 100 d8 q21d | 15–20% | 4–6 mo | 12–18 mo | Myelosuppression, Fluid retention, Fatigue. |
| Trabectedin | 1.5 mg/m² q21d (24h infusion) | 5–10% (High Disease Control Rate ~50-60%) | 4–5 mo | 12–15 mo | Hepatotoxicity, Myelosuppression, Nausea. Best for Leiomyosarcoma/Liposarcoma; modest activity in UPS. |
| Pazopanib | 800 mg PO Daily | 5–10% (DCR ~40-50%) | 3–4 mo | 12–14 mo | Hypertension, Proteinuria, Liver tox, Fatigue. Maintenance/2nd line. |
Immunotherapy
- Pembrolizumab / Nivolumab +/- Ipilimumab:
- UPS has higher TMB/PD-L1 than some sarcomas but lower than melanoma/lung.
- SARC028 / PEMBROSARC / NivoSarc trials: ORR ~15–20% (UPS subset ~20–25%).
- Durable responses seen in subset.
- Current Role: 2nd/3rd line (after chemo) or Clinical Trials. Not standard 1st line.
Targeted Therapy / Future Directions
- CDK4/6 Inhibitors (Palbociclib/Ribociclib): Only if CDK4 amplification proven (rare in true UPS; rules out Dediff Liposarcoma).
- PARP Inhibitors: ATRX/DAXX loss (ALT phenotype) – clinical trials ongoing.
- ADCs (Antibody-Drug Conjugates): Targeting antigens (e.g., FRα, B7-H3) – early phase trials.
8. Prognosis & Survival Outcomes
Prognosis is multifactorial. Nomograms (e.g., MSKCC Sarcoma Nomogram, EORTC/STBSG) integrate variables for individualized prediction.
Major Prognostic Factors (Multivariate Analysis)
| Factor | Favorable | Unfavorable |
|---|---|---|
| Tumor Size | ≤ 5 cm | > 10 cm (Major threshold) |
| Depth | Superficial (Subcutaneous) | Deep (Intramuscular/Retroperitoneal) |
| Surgical Margin | R0 (Wide) | R1 (Microscopic+) / R2 (Macroscopic+) |
| Grade (FNCLCC) | Grade 2 | Grade 3 (Most UPS) |
| Age | < 50–60 years | > 70 years |
| Site | Extremity (Distal > Proximal) | Retroperitoneum / Visceral |
| Necrosis | < 25% | > 50% |
| Metastasis at Dx | No (M0) | Yes (M1) |
| Radiation-Associated | Sporadic | Radiation-Induced (Worse biology, field constraints) |
Survival Statistics (Approximate, Contemporary Series)
| Stage / Scenario | 5-Year Overall Survival (OS) | 5-Year Local Recurrence Free Survival (LRFS) | 5-Year Distant Metastasis Free Survival (DMFS) |
|---|---|---|---|
| Localized, Resectable (Extremity) | 65–75% | 85–90% (with RT) | 60–70% |
| Localized, Resectable (Retroperitoneum) | 45–55% | 50–65% (High local recurrence) | 40–50% |
| Metastatic (Lung only, Resectable Mets) | 30–45% (Post-metastasectomy) | N/A | N/A |
| Metastatic (Unresectable / Systemic) | 12–18 months (Median OS) | N/A | N/A |
Local Recurrence: Occurs in 15–25% (Extremity+RT) to 40–60% (Retroperitoneum). Salvage surgery for isolated local recurrence can be curative** (5-yr OS post-salvage ~50%).
9. Follow-Up & Survivorship Care
Lifelong surveillance is mandatory due to risk of late recurrence (>5–10 years) and second malignancies (treatment-related).
Surveillance Schedule (NCCN / ESMO Guidelines)
| Timeframe | Clinical Exam | Chest Imaging | Primary Site Imaging (MRI) | Labs / Other |
|---|---|---|---|---|
| Years 1–2 | Every 3–4 months | Chest CT every 3–4 mo | MRI every 6–12 mo (if high risk/retroperitoneum) | CBC, CMP, LDH (optional trend). Echo if prior Doxo. |
| Years 3–5 | Every 6 months | Chest CT every 6 mo | MRI annually (or symptomatic) | Echocardiogram q1–2yr (if Doxo >300mg/m²). |
| Years 5+ | Annually | Chest CT annually (or Chest X-ray if low risk) | As clinically indicated | Long-term survivorship clinic. |
Late Effects Management
- Lymphedema: Common post groin/axillary dissection + RT. Early referral to Certified Lymphedema Therapist (CDT).
- Radiation Fibrosis/Contracture: Physical therapy, splinting, pentoxifylline + tocopherol (vitamin E) trial.
- Cardiotoxicity: LVEF monitoring (Echo/Strain imaging) for anthracycline recipients.
- Secondary Malignancies: Radiation-induced sarcoma (latency 10+ yrs), Therapy-related MDS/AML (alkylators/topoisomerase II inhibitors).
- Psychosocial: Fear of recurrence, body image, financial toxicity. Referral to psycho-oncology/support groups.
10. Patient Resources & Support
- Sarcoma Foundation of America (SFA): curesarcoma.org – Patient education, clinical trial finder, financial aid.
- Sarcoma UK / Sarcoma Patients EuroNet (SPAEN): European patient advocacy, multilingual resources.
- NCCN Guidelines for Patients®: Soft Tissue Sarcoma: Free, plain-language treatment guides (nccn.org/patients).
- ClinicalTrials.gov: Search “Undifferentiated Pleomorphic Sarcoma” + Location for active trials.
- Lymphedema Network / National Lymphedema Network (NLN): lymphnet.org – Therapist finder, compression garment info.
References
- WHO Classification of Tumours Editorial Board (2020) Soft tissue and bone tumours. 5th edn. Lyon: International Agency for Research on Cancer (WHO Classification of Tumours Series).
- Fletcher, C.D.M., Bridge, J.A., Hogendoorn, P.C.W. and Mertens, F. (eds.) (2013) WHO classification of tumours of soft tissue and bone. 4th edn. Lyon: IARC Press. (Note: 5th edition 2020 supersedes terminology).
- Guillou, L. et al. (2002) ‘Should we continue to use the term “malignant fibrous histiocytoma”? A multicenter study’, The American Journal of Surgical Pathology, 26(10), pp. 1289–1296.
- National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2.2024. Available at: https://www.nccn.org (Accessed: 24 May 2024).
- ESMO/EURACAN Clinical Practice Guideline Committee (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348–1365.
- Grignani, G. et al. (2017) ‘Sorafenib in advanced soft tissue sarcoma: a phase II trial’, European Journal of Cancer, 75, pp. 178–185. (Representative of targeted therapy trials).
- Schniederjan, M. et al. (2018) ‘Genomic landscape of undifferentiated pleomorphic sarcoma reveals distinct subsets with therapeutic implications’, Nature Communications, 9(1), p. 4166.
- Maki, R.G. et al. (2007) ‘A randomized phase II study of gemcitabine and docetaxel versus gemcitabine alone in patients with metastatic soft tissue sarcomas’, Journal of Clinical Oncology, 25(19), pp. 2755–2763.
- Judson, I. et al. (2014) ‘Doxorubicin alone versus doxorubicin plus ifosfamide in advanced soft tissue sarcoma: a randomised controlled trial’, The Lancet Oncology, 15(4), pp. 415–423.
- Tawbi, H.A. et al. (2017) ‘Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial’, The Lancet Oncology, 18(11), pp. 1493–1501.
- Gronchi, A. et al. (2012) ‘Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology and margin status are the main prognostic factors’, Journal of Clinical Oncology, 30(13), pp. 1558–1564.
- Bonvalot, S. et al. (2020) ‘Preoperative radiotherapy versus postoperative radiotherapy in retroperitoneal sarcoma (STRASS): a multicentre, open-label, randomised, phase 3 trial’, The Lancet Oncology, 21(11), pp. 1466–1477.
- Sinha, S. and Peabody, T.D. (2010) ‘Malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma’, Surgical Oncology Clinics of North America, 19(4), pp. 679–693.
- Antonescu, C.R. (2014) ‘The evolving classification of undifferentiated pleomorphic sarcoma’, Modern Pathology, 27(S1), pp. S34–S42.
- Cancer.Net Editorial Board (2023) Sarcoma – Soft Tissue: Statistics. American Society of Clinical Oncology. Available at: https://www.cancer.net/cancer-types/sarcoma-soft-tissue/statistics (Accessed: 24 May 2024).
Article prepared for medical information purposes. Last updated: May 2024. Next review due: May 2026.